EQL Pharma AB (publ) (STO:EQL)

Market Cap	2.48B
Revenue (ttm)	397.94M
Net Income (ttm)	42.54M
Shares Out	29.06M
EPS (ttm)	1.41
PE Ratio	60.60
Forward PE	40.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,830
Average Volume	26,912
Open	85.30
Previous Close	85.40
Day's Range	80.80 - 86.10
52-Week Range	51.00 - 98.60
Beta	0.64
RSI	40.52
Earnings Date	Jul 28, 2025

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EQL

Financial Performance

In 2024, EQL Pharma AB's revenue was 373.52 million, an increase of 41.39% compared to the previous year's 264.17 million. Earnings were 43.12 million, an increase of 89.93%.